Invest-in-America
2 months ago
MGRX: Come on, you dead-cat, BOUNCE!!! For the sake of us BIG-FAT-&-GREASY Amerikanos!!! And heck, you have one pill to make mens' DICKS big & fat --- and now another pill to make their OBESITY-BODIES "slim & trim"!!! Why not do BOTH in just one, tasty, fat pill???!!!
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
And see BELOW, what my own 'Personal Financial Planner' said to me early today, when I asked him what he thought about me tossin' some bucks at MGRX stock ---
Invest-in-America
2 months ago
MGRX: Hey, Admiral TW-0122, you know that I have BASHED this Firm many times in the past behind the TYPE of lurid ads they were running, but I NEVER mocked their substantive PRODUCT. Hey, Bro, I myself have been using it for MONTHS now. Heck, last Friday night, at a swingin' singles bar over here in (balmy) San Diego, CA, the hot chick in the bar security cam below almost got me BUSTED, Dude!!! And only 5-minutes after I had gulped a FIST FULL of MRGX's new pills!!!!
tw0122
2 months ago
ED to weight loss get hard then thin for the ladies a duo combo…lol
Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce the development of proprietary oral formulations of Semaglutide (“Slim”) and Tirzepatide (“Trim”) to aid in weight management. These innovative drugs, currently available predominantly in injectable form, have demonstrated remarkable efficacy in clinical trials. MangoRx’s new oral formulations are poised to revolutionize the weight loss market and capture significant market share.
The GLP-1 receptor agonists’ market, including both Semaglutide and Tirzepatide, is projected to reach over $164 billion in combined revenue by 2032, based on Visible Alpha consensus, ramping up from $37.9 billion in 2023. These are record-breaking revenues for any drug class in the history of drug development.
The oral formulations of Semaglutide and Tirzepatide are set to capture a significant share of this market, offering a convenient alternative to injections. Semaglutide, marketed under the brand names Ozempic® and Wegovy®, and Tirzepatide, marketed as Mounjaro® and Zepbound®, are both glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs have demonstrated impressive weight loss results in clinical trials. In a recent study, patients taking Semaglutide achieved an average weight loss of 15.2% over one year, while those taking Tirzepatide experienced an average weight loss of 15.7%. The oral formulations of Semaglutide and Tirzepatide are designed for daily consumption and are expected to provide similar weight loss benefits without the need for regular injections.
Patient preference studies consistently show a significant majority in favor of oral medications over injectables. This preference is anticipated to drive higher adoption rates and expand the existing market. The shift to an oral formulation offers a more accessible and convenient option for patients, potentially increasing adherence and overall treatment success.
“We are thrilled to introduce ‘Slim’ and ‘Trim’, MangoRx’s oral formulations of Semaglutide and Tirzepatide, to the weight loss market,” said Jacob Cohen, CEO and Co-Founder of MangoRx. “Our goal is to provide patients with a convenient and effective way to manage their weight and improve their overall health. We believe that these oral formulations have the potential to significantly impact the lives of millions of people worldwide.”
MangoRx plans to have the products available for customers on the company’s telemedicine platform in the beginning of the 3rd quarter with ‘Slim’ and ‘Trim’ competitively priced at $299/month and $399/month, respectively. MangoRx is committed to advancing the treatment of obesity and related conditions and is dedicated to improving the lives of patients worldwide.